# OnCo record paper-tannock-tax-327-docetaxel-prednisone-nejm-2004 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-tannock-tax-327-docetaxel-prednisone-nejm-2004" ;
schema:name "TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer"@en ;
schema:alternateName "TAX 327"@en, "Tannock 2004 docetaxel prostate"@en ;
schema:description "The first treatment ever shown to help men live longer once prostate cancer stopped responding to hormones. Docetaxel every three weeks added about two and a half months to median survival compared with the older drug, and made pain and quality of life better as well."@en ;
schema:url ;
schema:dateModified "2026-09-25"^^xsd:date ;
schema:citation , , ;
onco:tag "prostate-evidence" ;
schema:sameAs ;
schema:datePublished "2004"^^xsd:gYear ;
schema:author "Tannock IF, de Wit R, Berry WR, et al." ;
onco:related , , , , ;
onco:cancers , ;
onco:sections ;
onco:drugs , , ;
onco:terms , , , ;
onco:people , ;
onco:bottlenecks , ;
onco:journals .